HUMA
Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
+1.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1M | 2.0M | — | — | 1.6M |
| Cost of Revenue | 16.3M | 17.0M | 7.2M | 76.5M | 8.3M |
| Gross Profit | (14.1M) | (15.0M) | (7.2M) | (76.5M) | (6.7M) |
| Operating Expenses | |||||
| R&D Expense | 69.5M | 69.3M | 88.6M | 76.5M | 63.3M |
| SG&A Expense | 27.5M | 31.2M | 25.8M | 20.4M | 22.9M |
| General & Admin Expense | 16.0M | 31.2M | 25.8M | 23.4M | 22.9M |
| Selling & Marketing Expense | — | — | — | (3.0M) | — |
| Other Expenses | — | (8.0M) | (7.2M) | (73.4M) | (8.3M) |
| Total Operating Expenses | 97.0M | 92.4M | 107.2M | 23.5M | 77.9M |
| Cost and Expenses | 113.3M | 109.5M | 114.4M | 100.0M | 86.1M |
| Operating Income (EBIT) | (111.2M) | (107.4M) | (114.4M) | (100.0M) | (84.6M) |
| Non-Operating | |||||
| Interest Income | 1.8M | 2.6M | 4.1M | 5.5M | 2.6M |
| Interest Expense | 10.3M | 11.3M | 9.3M | 6.6M | 6.2M |
| Net Interest Income | (8.5M) | (8.7M) | (5.2M) | (1.1M) | (3.6M) |
| Other Non-Op Income/Expense | 14.4M | 66.6M | (34.3M) | (10.7M) | 72.6M |
| Non-Operating Income (excl Interest) | (24.7M) | (77.9M) | 25.0M | 4.1M | (78.8M) |
| EBT (Pre-Tax Income) | (96.7M) | (40.8M) | (148.7M) | (110.8M) | (12.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (96.7M) | (40.8M) | (148.7M) | (110.8M) | (12.0M) |
| Earnings from Cont. Ops | (96.7M) | (40.8M) | (148.7M) | (110.8M) | (12.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (96.7M) | (40.8M) | (148.7M) | (110.8M) | (12.0M) |
| Per Share | |||||
| Basic EPS | ($0.51) | ($0.26) | ($1.26) | ($1.07) | ($0.12) |
| Diluted EPS | ($0.51) | ($0.26) | ($1.26) | ($1.07) | ($0.12) |
| Revenue Per Share | $0.01 | $0.01 | $0.00 | $0.00 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 234.2M | 158.2M | 118.5M | 103.4M | 103.1M |
| Diluted Shares Outstanding | 234.2M | 158.2M | 118.5M | 103.4M | 103.1M |
| Profitability Metrics | |||||
| EBITDA | (79.7M) | (22.2M) | (132.2M) | (96.5M) | 2.4M |
| D&A | 6.8M | 7.3M | 7.2M | 7.7M | 8.2M |
| EBIT | (86.4M) | (29.6M) | (139.4M) | (104.2M) | (5.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026